Systems and methods for use of adenosine triphosphate (ATP) to relieve symptoms of COVID-19 and related infections
US12357651B2 · kind B2 · utility
0Cited by
4References
19Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | May 7, 2021 |
| Grant date | Jul 15, 2025 |
| Priority date | — |
| Expiry date | Jul 24, 2041 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P31/14
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Treatments for SARS-CoV-2 infection, COVID-19, symptoms of COVID-19, and similar infections. Specifically, treatments for patients identified as having Acute Respiratory Distress Syndrome (ARDS), and specifically COVID-19 ARDS, and/or suffering the effects of hypoxia. The treatments include increasing a patient's naturally occurring levels of ATP, adenosine, and/or other adenosine compounds.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.